Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 31, 2010
Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancerR B Costa, G Kurra, L Greenberg, et al.Southern Medical Journal|April 4, 2001
Breast conservation in the treatment of breast cancer: community-based experienceG P Swanson, K Rynearson, C E Geyer, et al.The American Journal of Medicine|March 1, 1987
Prinzmetal's angina during 5-fluorouracil chemotherapyN S Kleiman, D E Lehane, C E Geyer, et al.Breast Cancer Research and Treatment|January 8, 1999
Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group studyC E Geyer, S J Green, C M Moinpour, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2000
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignanciesE K Rowinsky, T R Johnson, C E Geyer, et al.Cancer|March 26, 1999
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinomaM L Rothenberg, J V Cox, R F DeVore, et al.Breast Cancer Research and Treatment|December 28, 2014
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II studyA R Tan, H Johannes, P Rastogi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2022
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trialC E Geyer, W M Sikov, J Huober, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2021
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINEE P Mamounas, M Untch, M S Mano, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 2, 2026
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancerP A Francis, O Pagani, G F Fleming, et al.Pageof 2